PhD9 antibody - AntoXa Corporation
Alternative Names: Anti-ricin antibody - AntoXa Corporation; ricin poisoning antidotes - AntoXa CorporationLatest Information Update: 06 Aug 2024
At a glance
- Originator Defence Research and Development Canada; SwiftPharma
- Developer Defence Research and Development Canada
- Class Antitoxins; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ricin poisoning
Most Recent Events
- 06 Aug 2024 PhD9 antibody is still in preclinical phase for Ricin poisoning in Canada (Parenteral) (AntoXa Corporation pipeline; August 2024)
- 06 Aug 2024 AntoXa Corporation and SwiftPharma collaborates to support the development and commercialization of PhD9 antibody for the treatment of Ricin Poisoning , mr addition req sent - https://antoxacorp.com/new-patent-for-antoxas-plant-made-anti-ricin-antibody-manufacturing-process/
- 28 May 2022 No recent reports of development identified for preclinical development in Ricin poisoning in Canada